James Graf - Dec 6, 2024 Form 4 Insider Report for NKGen Biotech, Inc. (NKGN)

Role: Chief Financial Officer
Signature: /s/ James Graf
Stock symbol: NKGN
Transactions as of: Dec 6, 2024
Transactions value $: $0
Form type: 4
Date filed: 12/10/2024, 09:55 PM
Previous filing: Dec 5, 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NKGN	Stock Option (right to buy)	Award	$0	+500K		$0.00	500K	Dec 6, 2024	Common Stock	500K	$0.44	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On December 6, 2024, the Reporting Person was granted 500,000 options pursuant to the Company's 2023 Equity Incentive Plan, with 25% vesting immediately as of the grant date, and the remaining options vesting in 36 equal installments on the sixth of each month, beginning January 6, 2025, and ending December 6, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

Content

On December 6, 2024, the Reporting Person was granted 500,000 options pursuant to the Company's 2023 Equity Incentive Plan, with 25% vesting immediately as of the grant date, and the remaining options vesting in 36 equal installments on the sixth of each month, beginning January 6, 2025, and ending December 6, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.